Evaluation of the VITEK 2 AST N-054 test card for the detection of extended-spectrum beta-lactamase production in Escherichia coli with CTX-M phenotypes

H Donaldson; M McCalmont; D M Livermore; P J Rooney; G Ong; E McHenry; R Campbell; R McMullan

doi:10.1093/jac/dkn316

Evaluation of the VITEK 2 AST N-054 test card for the detection of extended-spectrum beta-lactamase production in Escherichia coli with CTX-M phenotypes

H Donaldson, M McCalmont, D M Livermore, P J Rooney, G Ong, E McHenry, R Campbell, R McMullan

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

A new VITEK 2 antibiotic susceptibility testing (AST) card, AST N-054, was introduced for aerobic gram-negative bacilli in 2007 and has been widely adopted for routine use in the UK. We evaluated its performance for detecting extended-spectrum beta-lactamase (ESBL) production in Escherichia coli.

Original language	English
Pages (from-to)	1015-7
Number of pages	3
Journal	Journal of Antimicrobial Chemotherapy
Volume	62
Issue number	5
DOIs	https://doi.org/10.1093/jac/dkn316
Publication status	Published - Nov 2008

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jac/dkn316

Cite this

@article{1ad02bd751c8433284139c2240dbb602,

title = "Evaluation of the VITEK 2 AST N-054 test card for the detection of extended-spectrum beta-lactamase production in Escherichia coli with CTX-M phenotypes",

abstract = "A new VITEK 2 antibiotic susceptibility testing (AST) card, AST N-054, was introduced for aerobic gram-negative bacilli in 2007 and has been widely adopted for routine use in the UK. We evaluated its performance for detecting extended-spectrum beta-lactamase (ESBL) production in Escherichia coli.",

author = "H Donaldson and M McCalmont and Livermore, {D M} and Rooney, {P J} and G Ong and E McHenry and R Campbell and R McMullan",

year = "2008",

month = nov,

doi = "10.1093/jac/dkn316",

language = "English",

volume = "62",

pages = "1015--7",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "1460-2091",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Evaluation of the VITEK 2 AST N-054 test card for the detection of extended-spectrum beta-lactamase production in Escherichia coli with CTX-M phenotypes

AU - Donaldson, H

AU - McCalmont, M

AU - Livermore, D M

AU - Rooney, P J

AU - Ong, G

AU - McHenry, E

AU - Campbell, R

AU - McMullan, R

PY - 2008/11

Y1 - 2008/11

N2 - A new VITEK 2 antibiotic susceptibility testing (AST) card, AST N-054, was introduced for aerobic gram-negative bacilli in 2007 and has been widely adopted for routine use in the UK. We evaluated its performance for detecting extended-spectrum beta-lactamase (ESBL) production in Escherichia coli.

AB - A new VITEK 2 antibiotic susceptibility testing (AST) card, AST N-054, was introduced for aerobic gram-negative bacilli in 2007 and has been widely adopted for routine use in the UK. We evaluated its performance for detecting extended-spectrum beta-lactamase (ESBL) production in Escherichia coli.

U2 - 10.1093/jac/dkn316

DO - 10.1093/jac/dkn316

M3 - Article

C2 - 18669518

SN - 1460-2091

VL - 62

SP - 1015

EP - 1017

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 5

ER -

Evaluation of the VITEK 2 AST N-054 test card for the detection of extended-spectrum beta-lactamase production in Escherichia coli with CTX-M phenotypes

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this